Skip to content

Metabolic Modulators

Semaglutide

Weekly GLP-1 agonist with landmark evidence for weight loss, diabetes and heart protection; muscle preservation needs deliberate attention.

FDA approvedEvidence level 5 of 5: FDA-approved / large RCTsAlso: Ozempic, Wegovy, Rybelsus, Wegovy pill, Wegovy HD

Overview

Semaglutide mimics GLP-1, a gut hormone released after meals. It boosts glucose-dependent insulin release, suppresses glucagon, slows stomach emptying and acts on brain appetite centers to reduce hunger. A fatty-acid side chain lets it bind albumin, giving a one-week half-life. Large trials show about 15% average weight loss with the obesity dose, strong HbA1c reduction, a 20% drop in heart attacks, strokes and cardiovascular deaths, and kidney protection. A meaningful share of weight lost can be lean mass, so adequate protein and resistance training are essential, and much of the weight returns if the drug is stopped without a maintenance plan.

Classification
Long-acting acylated GLP-1 receptor agonist peptide (31 aa)
Route
Subcutaneous (weekly) or oral (daily)
Half-life
~7 days (SC)

Mechanism of action

Primary targetGLP-1 receptor (pancreas, brain, GI tract)
  1. Activates GLP-1 receptorAlbumin-bound peptide provides steady weekly receptor activation.
  2. Glucose-dependent insulinIncreases insulin and lowers glucagon only when glucose is elevated.
  3. Slows gastric emptyingProlongs fullness and blunts post-meal glucose spikes.
  4. Brain appetite signalingActs on hypothalamus and hindbrain to reduce hunger and cravings.
  5. Reduced energy intakeLower calorie intake drives sustained fat loss.
Downstream effects
  • ~15% weight loss
  • Lower HbA1c
  • Fewer cardiovascular events
  • Kidney protection

Researched for

  • Type 2 diabetes
  • Obesity and overweight
  • Cardiovascular risk reduction
  • MASH (fatty liver with fibrosis)
  • Chronic kidney disease in diabetes

Research notes

  • STEP-1 (NEJM 2021): 14.9% vs 2.4% weight loss at 68 weeks with the weekly obesity dose.
  • SELECT (NEJM 2023): 20% reduction in major adverse cardiovascular events in people with obesity and heart disease, without diabetes.
  • DEXA substudies suggest roughly a quarter to two-fifths of weight lost is lean mass; resistance training and protein mitigate this.
  • STEP-1 extension: about two-thirds of lost weight was regained within a year of stopping.

Reported side effects

  • Nausea, vomiting, diarrhea or constipation
  • Lean-mass loss alongside fat loss
  • Gallbladder disease
  • Pancreatitis (rare)
  • Hypoglycemia with insulin or sulfonylureas

Contraindications & cautions

  • Personal or family history of medullary thyroid carcinoma
  • Multiple endocrine neoplasia type 2 (MEN2)
  • Pregnancy (stop ≥2 months before conception)
  • History of pancreatitis (caution)
  • Severe gastroparesis

Lab monitoring

  • HbA1c and fasting glucose
  • Lipid panel
  • CMP (kidney and liver function)
  • Lipase if abdominal pain
  • Body composition (DEXA) to track lean mass

Dosing and pricing for Semaglutide

Dosing references and compound pricing are available to established patients in the secure portal after a medical evaluation.

Ready to take control of your health?

Start with a 60-minute physician evaluation, virtually in seven states or in person in Reston, Virginia.

Request a consultation 703-400-5314

Cash-pay. HSA and FSA accepted. Monday–Friday, 10 AM – 2 PM (virtual and in person).